Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Cancer research·2026
Same author

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.

Cell reports·2026
Same author

Prenatal PFAS Exposure in a Twin Pregnancy Cohort: Associations with Thyroid Disruption, Placental Malperfusion, and Fetal Growth Restriction.

Environmental science & technology·2026
Same author

Spatially tunable multiomic sequencing using light-driven combinatorial barcoding of molecules in tissues.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Cell fusion reprograms tumor cells and promotes RUNX1-mediated invasion and dissemination in colorectal cancer.

bioRxiv : the preprint server for biology·2026
Same author

Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma.

Nature medicine·2026

Related Experiment Video

Updated: May 26, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Spatially resolved transcriptomic and proteomic profiling reveals cell interaction programs that predict Barrett's

Isis Diaz Monarrez1, Eun Na Kim1,2, Krio Moon1

  • 1Department of Biomedical Engineering and Computational Biology Program, Oregon Health and Science University, Portland, OR, USA.

Biorxiv : the Preprint Server for Biology
|May 25, 2026
PubMed
Summary

Barrett's esophagus progression is driven by changes in tissue architecture, not just cell types. Spatial analysis accurately predicts risk, offering new avenues for early esophageal adenocarcinoma (EAC) detection.

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Related Experiment Videos

Last Updated: May 26, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Area of Science:

  • Gastroenterology
  • Oncology
  • Computational Biology

Background:

  • Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC).
  • Current surveillance methods struggle to predict BE progression.
  • The cellular landscape of progressing BE is poorly understood.

Purpose of the Study:

  • To investigate the premalignant cellular landscape of BE.
  • To identify spatial features predicting progression from non-dysplastic BE to dysplasia or EAC.
  • To differentiate progressor vs. non-progressor BE microenvironments.

Main Methods:

  • Spatial transcriptomics (Xenium) and proteomic imaging (imaging mass cytometry) on 34 BE patients.
  • Analysis of cellular composition, density, and spatial interactions.
  • T cell clonotype quantification (FUME-TCRseq).

Main Results:

  • Cellular composition was similar between progressors and non-progressors.
  • Progressors showed increased intestinal Barrett's cells, B cells, and gastric progenitor-like cells.
  • Spatial interaction features strongly predicted progression (AUC 0.97), outperforming cell composition (AUC 0.62).
  • Progressors had enriched cytotoxic/antigen-presenting myeloid cells; non-progressors had CD56+ T cell interactions.

Conclusions:

  • BE progression is driven by epithelial-immune-stromal architecture remodeling.
  • Spatial tissue architecture, not just cell types, captures progression states.
  • This framework enables spatially informed patient stratification and early cancer risk assessment.